News | February 21, 2024
AstraZeneca completes acquisition of Icosavax
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The 200 bedded hospital owned & operated by Alexis
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Subscribe To Our Newsletter & Stay Updated
